Last reviewed · How we verify

NCT03931018: BINGE

Biomarkers of Alcohol After an Experimental Administration of Alcohol Simulating a "Binge Drinking" Episode

Status unknown NA Last updated 29 April 2019
What this trial tests

NA trial testing Alcohol in Binge Drinking in 36 participants. Status unknown.

Timeline
1 December 2017
Primary endpoint
31 December 2019
1 March 2020

Quick facts

Lead sponsorFundació Institut Germans Trias i Pujol
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingsingle
Primary purposebasic science
Enrollment36
Start date1 December 2017
Primary completion31 December 2019
Estimated completion1 March 2020
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Fundació Institut Germans Trias i Pujol — full company profile →

Who can join

Adults 18 to 35, any sex, with Binge Drinking or Alcohol-Related Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purposes of this study are 1) to determine the pharmacokinetics of alcohol after experimental administration of alcohol simulating a "binge-drinking" episode in young adults 2) to determine the profile of biomarkers of acute damage and exposure/consumption to alcohol 3) to determine the pharmacokinetic parameters and evaluate the acute effects alcohol and its relationship with biomarkers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Alcohol

Trials testing the same drug.

Other recruiting trials for Binge Drinking

Currently open trials in the same condition.

Other Fundació Institut Germans Trias i Pujol trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03931018.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing